Shire said the US Food and Drug Administration granted the designation for SHP621 (budesonide oral suspension or BOS) for eosinophilic oesophagitis (EoE), an inflammatory condition of the ...
The US regulator has cleared Eohilia (formerly TAK-721), an oral suspension formulation of the well-established steroid drug budesonide, for people 11 years and older with EoE after turning down ...
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486 Technology appraisal guidance Targeted-release budesonide for treating primary IgA ...
Budesonide (micronized ... Each single-dose Respules ampule contains 2 mL of sterile liquid suspension. Pulmicort Respules is available in 3 strengths, each containing 2 mL: Pulmicort Respules ...
In February 2024, the US FDA approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with EoE. In January 2024, US FDA approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results